bioMerieux SA

What does bioMerieux own?

bioMerieux owns diagnostic product families including BIOFIRE, SPOTFIRE, VITEK, and VIDAS, plus subsidiaries such as BioFire Diagnostics in the United States. Its business is instruments, reagents, and software rather than consumer brands.

Is bioMerieux publicly traded?

Yes. bioMerieux trades on Euronext Paris under ticker BIM and is part of the SBF 120 index. The Merieux family retains majority control through Institut Merieux.

Who founded bioMerieux?

Alain Merieux founded the modern company in 1963, building on the family medical enterprise started by his father Marcel Merieux in 1897. The family has controlled the business for four generations.

Where is bioMerieux headquartered?

The company is headquartered in Marcy l'Etoile, a suburb of Lyon in the Auvergne-Rhone-Alpes region of France. Its largest manufacturing and R&D site outside France is in Salt Lake City, Utah.

How many brands does bioMerieux own?

Its portfolio centers on a small set of product families rather than many brands: BIOFIRE, SPOTFIRE, VITEK, VIDAS, and the BioFire Diagnostics subsidiary that makes them. It owns roughly a dozen significant product lines.

Who owns bioMerieux?

The Merieux family holds a majority stake through Institut Merieux and Compagnie Merieux Alliance. The remaining shares trade publicly on Euronext Paris and are held by institutional and retail investors.

What is bioMerieux's revenue?

The company reported sales of 4,070 million euros for fiscal year 2025, up 6.2 percent organically, with contributive operating income before non-recurring items of 728 million euros.

The company's roots reach to 1897, when Marcel Merieux, a student of Louis Pasteur, founded Institut Merieux in Lyon. The modern bioMerieux entity was created in 1963 by Alain Merieux, Marcel's son, initially as a diagnostics arm of the family's medical enterprises under the name B-D Merieux, reflecting an early partnership with Becton Dickinson.

Alain Merieux built the business into an independent diagnostics leader, developing the API biochemical test strips for bacterial identification and later the VITEK automated microbiology systems that became global standards in clinical laboratories. The company listed on the Paris stock market in 2004.

International expansion came through both organic growth and acquisition. Major purchases included Organon Teknika's diagnostics business in the early 2000s, the US molecular diagnostics firm BioFire Diagnostics in January 2014 for approximately 450 million dollars, and the food-safety testing business AES Chemunex. The BioFire deal in particular transformed the company, making syndromic PCR testing its largest single product family.

Leadership passed from Alain Merieux to his son Alexandre, who served as chairman and CEO before separating the roles in July 2023. Alexandre Merieux is executive chairman and Pierre Boulud, a company veteran since 2016, is chief executive. Under the GO-28 strategic plan, the company is concentrating on four growth drivers: BIOFIRE non-respiratory panels, the SPOTFIRE platform, microbiology, and industrial applications. In May 2026 it announced a 250 million euro BIOFIRE production facility at La Balme-les-Grottes in France, expected to create about 400 jobs and open by 2030.

The company publishes annual sustainability reporting within its universal registration document and has committed to science-based emissions targets. Its public-health mission is central to its ESG framing, particularly around antimicrobial resistance, where diagnostics that identify pathogens quickly are treated as a public-health good.

Because most of its revenue is diagnostics rather than consumer goods, traditional consumer sustainability flags such as cruelty-free certification do not apply. Its more relevant disclosures concern responsible laboratory practices, supply-chain ethics, and the footprint of its manufacturing network.

bioMerieux's regulatory exposure is typical of a diagnostics maker: periodic FDA warning letters, product corrections, and field recalls tied to specific assays or instruments. It has faced voluntary recalls of certain VITEK and VIDAS components over the years, resolved through corrective actions.

The company has also received scrutiny over the accuracy of particular tests and over data handling in connected instruments, but has avoided the large-scale scandals that have hit some peers. Its family-controlled governance occasionally draws governance-ratings criticism for concentrated control, an inherent feature rather than a violation.